The prevalence of asthma, particularly in children, has increased globally in recent decades. As a pediatrician, I was pleased to see that guidelines for the treatment of childhood asthma were recently published by the Global Initiative for Asthma. 1 These guidelines provide a good consensus for the diagnosis and treatment of childhood asthma, even in children younger than 5 years old. Asthmacontrolling medication that tastes good and is administered by user-friendly devices has been shown to prevent asthma symptoms and improve lung function.
Most children with asthma have mild-to-moderate asthma, which usually responds to low-dose inhaled corticosteroids (ICS) or to nonsteroidal antiinflammatory drugs, such as leukotriene antaonists, theophylline and ketotifen. For children with moderate-to-severe asthma, double doses of ICS or oral corticosteroids can usually control the asthma symptoms and effectively prevent attacks. Alternatively, add-on subcutaneous immunotherapy with extracts of specific allergens has been shown to be effective for hay fever and asthma. In Taiwan, the most common allergens are Dermatophagoides pteronyssinus (Der P) and Dermatophagoides farinae (Der F). Previous studies have demonstrated that subcutaneous or sublingual immunotherapy with house dust mites or their antigens, Der P and Der F, had beneficial effects in children with asthma, in terms of decreased symptom scores and medication requirements. A study by Tsai et al 2 reported
in this issue, reproduced the beneficial effects of subcutaneous immunotherapy with Der P and Der F allergens on the control of childhood asthma. Recent studies have introduced the use of a combination of specific allergen immunotherapy with anti-IgE (omalizumab) treatment in patients with moderate-to-severe asthma; it was demonstrated that pretreatment with the monoclonal anti-IgE antibody for 9 weeks reduced systemic reactions during rush immunother apy five-fold. 3 Moreover, clinical trials with Toll-like receptor 9 vaccines conjugated to a ragweed allergen or with antiinterleukin-5 therapy have been shown to be effective as corticosteroid-sparing agents in patients with allergic disorders. 4 However, asthma is usually not curable, even with ICS, immunotherapy, and/or anti-IgE (omalizumab) therapy.
Asthma is a complex disease whose reversibility and progression is affected by chronic inflammation, hyperresponsiveness, and neuromuscular remodeling. It is therefore necessary to identify the roles of these complex compartments in the reversal or progression of asthma. To this end, another study in this issue by Kuo et al 5 demonstrated that the administration of different brands of ICS to asthmatic children reduced asthma symptoms, but induced varying effects on the production of cytokines and exhaled nitric oxide levels. Asthma appears to be a complex disease that can remit or progress and can respond to environmental factors, including medication.
Asthma has long been recognized as a hereditary disorder. However, the prevalence of childhood asthma in different countries ranges from less than 1% in Tibet (China) to greater than 30% in New Zealand. Various genome-wide studies have identified more than 100 genes on 22 chromosomes that are associated with asthma.
6−8 A number of studies also found different genetic backgrounds in different environments could modulate susceptibility to different allergic disorders. 9, 10 This suggests that allergic diseases, although heritable, are significantly affected by environmental factors that can modulate the progression or remission of asthma via epigenetic programming.
The influence of the perinatal environment on the epigenetic programming of adult diseases has been linked to diabetes, cardiovascular diseases and kidney diseases. It has also been postulated that certain genes can be epigenetically modified by environmental factors during the perinatal stage, thus priming individuals to develop childhood asthma and rhinitis. To this end, we have been studying a birth cohort from the antenatal stage to 6 years old to clarify the effects of the gene-environment interaction on the development of asthma. Progress reports of this cohort study have shown that certain genes can interact with maternal atopy to affect prenatal IgE production and atopic dermatitis.
11−13
However, a different gene which is not correlated to allergy sensitization, is involved in the development of infant wheezing.
14 Further studies have investigated the occurrence of epigenetic programming of asthma and rhinitis during the perinatal stage in this cohort. Clarification of the perinatal epigenetic programming of childhood asthma and rhinitis may highlight prospects for the early prediction and prevention of childhood asthma and rhinitis by epigenetic modulation.
